BP-lowering treatment across the spectrum of CV riskHot Line 9Hypertension
Blood Pressure-Lowering Treatment Across Cardiovascular Risk Spectrum
Blood pressure-lowering treatment across the spectrum of cardiovascular risk: an individual patient data meta-analysis
Overview
Awaiting these results before revising BP thresholds in lower-risk groups; this IPD meta-analysis will extend prior syntheses on treatment benefit across risk strata.
Key result
Blood pressure-lowering treatment across the spectrum of cardiovascular risk is being evaluated in an individual patient data meta-analysis, with results currently pending.
Discussion
Expert reaction lands here the moment BP-lowering treatment across the spectrum of CV risk reports.
Expert takes
This individual patient data meta-analysis pooled data from 48 randomised clinical trials (~345,000 patients) and found that a 5mmHg reduction in systolic blood pressure reduced major cardiovascular events by about 10%, irrespective of prior CVD diagnosis or baseline blood pressure level—even at "normal" values. The findings challenge the notion of a threshold for BP-lowering treatment and support a risk-based rather than hypertension-based approach to treatment decisions. Quote supply is very limited, with only lead author quotes available from one news source.
Kazem Rahimi
Professor of cardiovascular medicine, University of Oxford
“This most detailed study of randomised trials should end the long-standing controversy around the existence of any thresholds for pharmacological blood pressure lowering. We provide compelling evidence for the beneficial effects of blood pressure-lowering treatment across the spectrum of systolic blood pressure in people with or without a known diagnosis of cardiovascular disease.”
Key Points
- Investigation evaluates the efficacy of blood pressure-lowering treatment across diverse levels of baseline cardiovascular risk in patient cohorts.
- Individual patient data meta-analysis synthesizes trial records to compare clinical outcomes across stratified cardiovascular risk profiles.
- Highlights potential refinement of clinical guidelines for hypertension management, though final efficacy results remain pending presentation.
Main Result
Absolute Event Rate: 0% vs 0%